{"article_title": "Hillary vs. Cancer Treatment", "article_keywords": ["twothirds", "threequarters", "clinton", "unfortunately", "cancer", "unreasonable", "drug", "hillary", "vs", "survey", "treatment", "prices", "survive"], "article_url": "http://www.wsj.com/articles/hillary-vs-cancer-treatment-1443007218", "article_text": "Hillary Clinton sent biotech stocks plunging Tuesday as she rolled out her plan to limit drug prices. A Journal editorial notes that Mrs. Clinton also intends to \u201cset quotas for research and development, though one of five U.S. R&D dollars are deployed by drug makers.\u201d She will unfortunately find a receptive audience. In a recent survey nearly three-quarters of respondents said they believed drug costs are \u201cunreasonable.\u201d Cancer drugs consume just 1% of U.S. health spending, but when prices seem high it can be easy to forget about benefits. \u201cTwo-thirds of Americans now survive at least five years after a cancer...", "article_metadata": {"article.template": "snippet", "article.created": "2015-09-23T11:20:00.000Z", "article.section": "Opinion", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Clinton wants to regulate drug prices, Bush wants to cap all federal regulation; Holman Jenkins explains the disaster at VW.", "creator": "@FreemanWSJ", "image": {"src": "https://si.wsj.net/public/resources/images/BN-KL113_MEr092_G_20150923074909.jpg", "alt": "Hillary vs. Cancer Treatment", "identifier": "https://si.wsj.net/public/resources/images/BN-KL113_MEr092_D_20150923074909.jpg"}, "title": "Hillary vs. Cancer Treatment", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB11559093491392963941204581250532615552512&headline=Hillary%20vs.%20Cancer%20Treatment&weburl=http://www.wsj.com/articles/SB11559093491392963941204581250532615552512"}}, "page.site.product": "WSJ", "keywords": "regulation,government policy,new products,services,research,development,new product approvals,corporate,industrial news,new product,service testing,biotechnology,cancer,political,general news,cancer research,health,medical conditions,sciences,humanities,commentaries,opinions,pharmaceuticals,health care,life sciences", "news_keywords": "regulation,government policy,new products,services,research,development,new product approvals,corporate,industrial news,new product", "article.headline": "Hillary vs. Cancer Treatment", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-KL113_MEr092_E_20150923074909.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-KL113_MEr092_D_20150923074909.jpg"}}, "description": "Clinton wants to regulate drug prices, Bush wants to cap all federal regulation; Holman Jenkins explains the disaster at VW.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB11559093491392963941204581250532615552512&headline=Hillary%20vs.%20Cancer%20Treatment&weburl=http://www.wsj.com/articles/SB11559093491392963941204581250532615552512", "user.type": "nonsubscriber", "article.page": "Commentary", "page.content.format": "responsive", "article.summary": "Clinton wants to regulate drug prices, Bush wants to cap all federal regulation; Holman Jenkins explains the disaster at VW.", "page.site": "wsj", "testkeys": "C", "article.published": "2015-09-23T11:37:00.000Z", "dj.asn": "i-c642", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "embed_count": 1, "image_count": 1, "word_count": 475, "internal_link_count": 17}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Clinton wants to regulate drug prices, Bush wants to cap all federal regulation; Holman Jenkins explains the disaster at VW.", "title": "Hillary vs. Cancer Treatment", "url": "http://www.wsj.com/articles/hillary-vs-cancer-treatment-1443007218", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-KL113_MEr092_G_20150923074909.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "James Freeman", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Hillary vs. Cancer Treatment", "article.type": "Morning Editorial Report", "article.id": "SB11559093491392963941204581250532615552512", "user.exp": "default", "article.updated": "2015-09-23T11:37:00.000Z"}, "article_summary": "Hillary Clinton sent biotech stocks plunging Tuesday as she rolled out her plan to limit drug prices.\n\u201cTwo-thirds of Americans now survive at least five years after a cancer...\nIn a recent survey nearly three-quarters of respondents said they believed drug costs are \u201cunreasonable.\u201d Cancer drugs consume just 1% of U.S. health spending, but when prices seem high it can be easy to forget about benefits.\nA Journal editorial notes that Mrs. Clinton also intends to \u201cset quotas for research and development, though one of five U.S. R&D dollars are deployed by drug makers.\u201d She will unfortunately find a receptive audience."}